| Cash Flow | 2025-08-31 |
|---|---|
| Net loss | 11,911,434 |
| Stock based compensation | 859,494 |
| Depreciation and amortization | 87,825 |
| Impairment loss | 247,364 |
| Bad debt expense | 0 |
| Noncash lease expense | 28,027 |
| Unrealized loss on marketable securities | -33,714 |
| Lease accretion | 9,047 |
| Accounts receivable | 213,881 |
| Prepaid expenses and deposits | -55,313 |
| Long-term receivables | 438 |
| Accounts payable and accrued liabilities | 396,637 |
| Operating lease liability | -37,093 |
| Deferred revenue | -4,962 |
| Net cash used in operating activities | -10,450,387 |
| Short-term investments | 143,267 |
| Additions to intellectual property | 75,106 |
| Purchase of equipment | 24,646 |
| Net cash used in investing activities | -243,019 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from shares sold for cash | 6,046,163 |
| Proceeds from exercise of warrants | 0 |
| Net cash provided by financing activities | 6,046,163 |
| Effect of exchange rate changes on cash | -50,519 |
| Net change in cash for the period | -4,697,762 |
| Cash and cash equivalents at beginning of period | 6,499,885 |
| Cash and cash equivalents at end of period | 1,802,123 |
Lexaria Bioscience Corp. (LEXX)
Lexaria Bioscience Corp. (LEXX)